Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
473 questions in 36 reviews · HIV/AIDS
current versionsNo studies 38 · 8%Ungraded 9 · 1.9%Very low 126 · 26.6%Low 127 · 26.8%Moderate 152 · 32.1%High 21 · 4.4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mma Bana continued: AZT/3TC/LPV‐r vs AZT/3TC/ABC Maternal Mortality at Six Months · HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.35 [0.01, 8.44] | 1 study · 560 participants | Low |
Mma Bana continued: AZT/3TC/LPV‐r vs AZT/3TC/ABC Mother to Child Transmission In Utero Positive HIV DNA PCR Within 96 Hours · HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.35 [0.04, 3.34] | 1 study · 553 participants | Low |
Mma Bana continued: AZT/3TC/LPV‐r vs AZT/3TC/ABC Mother to Child Transmission Late Postpartum Negative HIV DNA PCR at Birth and One Month, But Positive HIV DNA PCR at Six Months · HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.21 [0.01, 4.35] | 1 study · 553 participants | Low |
Mma Bana continued: AZT/3TC/LPV‐r vs AZT/3TC/ABC Mother to Child Transmission at Six Months Post‐Partum All Positive HIV DNA PCRs at Six Months · HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.17 [0.02, 1.44] | 1 study · 553 participants | Low |
Bae: AZT/3TC/NVP vs AZT (+/‐ single dose NVP) HIV‐Transmission or Death at 7 Months · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.39 [0.18, 0.85] | 1 study · 178 participants | Very low |
Bae: AZT/3TC/NVP vs AZT (+/‐ single dose NVP) Infant Grade 3/4 Severe Adverse Events at Birth · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 1.26 [0.35, 4.54] | 1 study · 178 participants | Very low |
Bae: AZT/3TC/NVP vs AZT (+/‐ single dose NVP) Prematurity · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.56 [0.21, 1.5] | 1 study · 178 participants | Very low |
Bae: AZT/3TC/NVP vs AZT (+/‐ single dose NVP) Mother to Child Transmission at Birth · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.18 [0.02, 1.36] | 1 study · 178 participants | Very low |
Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) Infant Mortality at 6 Months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.78 [0.43, 1.42] | 1 study · 781 participants | Moderate |
Bae: AZT/3TC/NVP vs AZT (+/‐ single dose NVP) Mother to Child Transmission at 1 Month · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.23 [0.05, 0.96] | 1 study · 178 participants | Very low |
Bae: AZT/3TC/NVP vs AZT (+/‐ single dose NVP) Mother to Child Transmission Cumulative by 7 Months · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.15 [0.04, 0.62] | 1 study · 178 participants | Very low |
Ekouevi: AZT/3TC/NVP vs Other Short Course PMTCT Regimen Stillbirths · ART‐Eligible HIV‐infected Pregnant Women Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 1.16 [0.34, 3.93] | 1 study · 326 participants | Very low |
Ekouevi: AZT/3TC/NVP vs Other Short Course PMTCT Regimen Infant Low Birth Weight · ART‐Eligible HIV‐infected Pregnant Women Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 1.81 [1.09, 3] | 1 study · 309 participants | Very low |
Ekouevi: AZT/3TC/NVP vs Other Short Course PMTCT Regimen Mother to Child Transmission at 12 Months · ART‐Eligible HIV‐infected Pregnant Women Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.14 [0.04, 0.47] | 1 study · 311 participants | Very low |
Jamisse (What to Start): AZT/3TC/NVP vs d4T/3TC/NVP Maternal Grade 3/4 Severe Adverse Events · HIV‐Infected Pregnant Women With CD4<350 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 1.58 [0.6, 4.12] | 1 study · 146 participants | Very low |
Jamisse (When to Start): AZT/3TC/NVP for CD4 250‐350 vs AZT/3TC/NVP Maternal Grade 3/4 Severe Adverse Events · HIV‐Infected Pregnant Women1 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 1.18 [0.47, 2.97] | 1 study · 146 participants | Very low |
Marazzi: AZT/3TC/NVP for HIV Infection in Pregnant Women With CD4 <250 vs >250 cells/mm3 Maternal Grade 3/4 Hepatotoxicity · HIV‐infected Pregnant Women Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.64 [0.34, 1.2] | 1 study · 703 participants | Ungraded |
Phanuphak: AZT/3TC/NVP (PMTCT) vs AZT/3TC/NVP (ART) Maternal Grade 3/4 Severe Adverse Events · HIV‐1 Infected Pregnant Women Who Have CD4>200 Compared with Those Who Have CD4<200 Cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 1.98 [0.65, 6.03] | 1 study · 244 participants | Very low |
Tonwe‐Gold: AZT/3TC/NVP vs Other Short Course Regimen HIV Transmission or Death at 1 Month · HIV‐Infected Pregnant Women Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.86 [0.25, 2.97] | 1 study · 218 participants | Very low |
Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) Infant Mortality at 12 months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.63 [0.38, 1.03] | 1 study · 751 participants | Low |
Tonwe‐Gold: AZT/3TC/NVP vs Other Short Course Regimen HIV Transmission or Death at 12 Months · HIV‐Infected Pregnant Women Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.86 [0.42, 1.77] | 1 study · 189 participants | Very low |
Tonwe‐Gold: AZT/3TC/NVP vs Other Short Course Regimen Infant Mortality at 1 Month · HIV‐Infected Pregnant Women Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 1.33 [0.27, 6.47] | 1 study · 231 participants | Very low |
Tonwe‐Gold: AZT/3TC/NVP vs Other Short Course Regimen Maternal Grade 3/4 Severe Adverse Events Requiring Treatment Modification · HIV‐Infected Pregnant Women Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 25.33 [1.49, 430.51] | 1 study · 250 participants | Very low |
Tonwe‐Gold: AZT/3TC/NVP vs Other Short Course Regimen Infant Low Birth Weight · HIV‐Infected Pregnant Women Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 2.17 [1.23, 3.81] | 1 study · 231 participants | Very low |
Tonwe‐Gold continued: AZT/3TC/NVP vs Other Short Course Regimen Stillbirths · HIV‐Infected Pregnant Women Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.89 [0.26, 3.08] | 1 study · 241 participants | Very low |
Tonwe‐Gold continued: AZT/3TC/NVP vs Other Short Course Regimen Maternal Mortality at Delivery · HIV‐Infected Pregnant Women Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | no estimate extracted | 1 study · 241 participants | Very low |
Tonwe‐Gold continued: AZT/3TC/NVP vs Other Short Course Regimen Mother to Child Transmission of HIV at 1 Month · HIV‐Infected Pregnant Women Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.32 [0.04, 2.83] | 1 study · 217 participants | Very low |
Tonwe‐Gold continued: AZT/3TC/NVP vs Other Short Course Regimen Mother to Child Transmission of HIV at 12 Months · HIV‐Infected Pregnant Women Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.4 [0.11, 1.41] | 1 study · 188 participants | Very low |
Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) Maternal Grade 3/4 Severe Adverse Events · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 1.09 [0.77, 1.53] | 1 study · 824 participants | Very low |
Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) Infant Grade 3/4 Severe Adverse Events · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.95 [0.77, 1.16] | 1 study · 805 participants | Low |
Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) Prematurity · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 1.23 [0.85, 1.79] | 1 study · 805 participants | Very low |
Kesho Bora continued: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) Low Birth Weight · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 1.46 [0.94, 2.25] | 1 study · 805 participants | Low |
Kesho Bora continued: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) Stillbirths · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 1 [0.25, 3.95] | 1 study · 824 participants | Low |
Intervention NR Mortality, all‐cause · patients with diarrhoea in children with HIV infection Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection (2010) · Cochrane | RR 0.5 [0.31, 0.79] | 3 studies · 267 participants | Low |
Intervention NR Incidence acute diarrhea number of episodes per number of months · patients with HIV exposure (children) Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection (2010) · Cochrane | RR 0.92 [0.67, 1.26] | 1 study · 538 participants | Low |
Intervention NR Incidence persistent diarrhea number of episodes per number · patients with HIV exposure (children) Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection (2010) · Cochrane | RR 0.86 [0.44, 1.67] | 1 study · 538 participants | Low |
Intervention NR Hospitalisations for diarrhoea number of episodes per number · patients with HIV exposure (children) Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection (2010) · Cochrane | no estimate extracted | 1 study · 538 participants | Low |
Intervention NR Severity diarrhoea ‐ not reported · patients with HIV exposure (children) Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection (2010) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Upper Respiratory Tract Infection number of episodes per number of months · patients with HIV exposure (children) Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection (2010) · Cochrane | RR 0.85 [0.7, 1.04] | 1 study · 538 participants | Low |
Intervention NR Mortality, all‐cause · patients with HIV infection or exposure Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection (2010) · Cochrane | RR 0.31 [0.07, 1.42] | 1 study · 96 participants | Low |
Intervention NR Mortality, diarrhea‐specific · patients with HIV infection or exposure Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection (2010) · Cochrane | RR 0.22 [0.01, 4.4] | 1 study · 96 participants | Low |
Intervention NR Visits for watery diarrhoea number of visits with diagnosis watery diarrhoea/all visits · patients with HIV infection or exposure Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection (2010) · Cochrane | RR 0.51 [0.34, 0.76] | 1 study · 854 participants | Low |
Intervention NR Pneumonia number of visits with diagnosis pneumonia/all visits · patients with HIV infection or exposure Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection (2010) · Cochrane | RR 0.75 [0.55, 1.03] | 1 study · 854 participants | Low |
Intervention NR Upper Respiratory Infections number of visits with diagnosis URI/all visits · patients with HIV infection or exposure Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection (2010) · Cochrane | RR 1.09 [0.92, 1.29] | 1 study · 854 participants | Low |
Intervention NR Mortality, diarrhoea‐specific · patients with diarrhoea in children with HIV infection Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection (2010) · Cochrane | RR 0.26 [0.03, 2.26] | 2 studies · 829 participants | Very low |
Intervention NR Severe adverse events ‐ not reported · patients with HIV infection or exposure Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection (2010) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Anthropometric outcomes ‐ not reported · patients with HIV infection or exposure Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection (2010) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Mortality, all‐cause · patients with HIV infection or exposure Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection (2010) · Cochrane | HR 0.57 [0.43, 0.77] | 1 study · 534 participants | Moderate |
Intervention NR Mortality, all cause3 · patients with HIV infection or exposure Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection (2010) · Cochrane | no estimate extracted | 2 studies · 872 participants | Very low |
Intervention NR Mortality, diarrhoea‐specific hospital deaths due to diarrhoea and/or dehydration · patients with HIV infection or exposure Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection (2010) · Cochrane | RR 0.51 [0.15, 1.67] | 1 study · 534 participants | Low |